Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic
  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Global WholeHealth Partners Corp (GWHP-OTC) has Signed an Agreement With Dr. Vu Le to be the Medical Director for the CLIA WAIVED Mobile Laboratory

Global Will be Using All CLIA WAIVED Lab to Test for COVID 19 Antigen, Antibody, and the Other 15 Tests that are CLIA WAIVED that Global Carries; Company is Bringing Testing to Patients at Schools & Work

San Clemente, CA - (NewMediaWire) - June 02, 2021 - Global WholeHealth Partners Corp. (OTC: GWHP), a company that offers one of the largest lines of COVID 19 tests including SARS-CoV-2 viruses and that states that its Antibody IgG/IgM tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses, today announced that they will be bringing their tests directly to the homes and offices of patients in need. To help implement this outreach program, the Company has signed an agreement with Dr. Vu Le to be the Medical Director for the Company’s CLIA WAIVED Mobile Laboratory.

The Company offers one of the largest lines of COVID 19 tests, including the strains identified in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) strain contains multiple mutations, most reflected in the S gene, which encodes the spike protein.

Global WholeHealth Partners Corp. (OTC: GWHP) provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines for detection of SARS-CoV-2 IgM/IgG antibodies in human serum, plasma, or whole blood. It has led the fight against vector borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruses, and among other vector borne diseases, with an FDA Certificate of Exportability (2260-11-2019). The company was founded on March 7, 2013 and is headquartered in San Clemente, CA.

Mr. Charles Strongo, the CEO and Chairman of Global WholeHealth Partners Inc., said: “Global understands the need to be aheadof the virus to conquerthe virus. We recognize that there is a crucial need for faster testing and faster results when it comes to fighting the COVID. Global WholeHealth Partners knows that the quicker the test results can be reviewed by a Front-Line Healthcare Worker, the quicker we can stop the spread of this disease.”

Dr. Vu Le has been a practicing physician for more than 10 years and knows the value of being able to bring testing to the people.

Mr. Strongo continued: “We are happy to have added Dr. Le to our team. He will create, coordinate and implement our push to have children at school and adults at work to get vaccinated as quickly as possible.”

About Global WholeHealth Partners Corp

GWHP develops, manufactures, and markets in vitro diagnostic (IVD) tests for OTC, or consumer-use as well as professional rapid diagnostic point-of-care (POC) test kits for hospitals, physicians' offices, and medical clinics in the US and abroad. The Company has the capacity to deliver hundreds of thousands of tests and can ramp up to 1 million tests per day and the Company presently has 56 products FDA approved and many are Approved for OTC use, and 9 POC products approved by the FDA, many of which are approved for OTC use, and 15 POC products approved by the CLIA WAIVED FDA.

Media connection: Charles Strongo

Phone for Sales: 714-392-3423

Sales@GWHPCORP.COM

For more information please go to:www.gwhpcorp.com

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

View original content to download multimedia: http://www.prnewswire.com/news-releases/alzheimers-disease-is-the-leading-cause-of-dementia-alzheimers-diagnostics-attained-by-global-wholehealth-partners-corp-otc-gwhp-as-a-leading-researcher-301285232.html

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.